Literature DB >> 29131244

A review on irisin, a new protagonist that mediates muscle-adipose-bone-neuron connectivity.

B Grygiel-Górniak1, M Puszczewicz.   

Abstract

Physical activity improves the quality of life and decreases the risk of several diseases (i.e. stroke, hypertension, myocardial infarction, obesity, and malignancies). Skeletal muscles are considered as an endocrine organ that produces myokines characterized by a paracrine or endocrine activity. Irisin is a circulating hormone-like myokine and is secreted as a product of fibronectin type III domain-containing protein 5 from skeletal muscle in response to exercise. This molecule regulates the energy metabolism and acts in adipose tissue, bones, and nervous system. As both animal and clinical studies confirmed the action of irisin in muscle and adipocytes, this protein is considered as adipomyokine. In adipose tissue, irisin stimulates the process of browning of beige precursor fat cells, which are present in white fat cells, and promotes energy expenditure. It affects bone metabolism by increasing osteoblast differentiation and reducing osteoclast maturation. In the nervous system, irisin influences hippocampal neurogenesis and neural differentiation of embryonic stem cells in mice and is considered as a messenger between exercise and brain function. However, the existence of this protein and its role in humans is a matter of debate. This study presents irisin as a new champion of the molecule, which could be considered as the messenger in the muscle-fat-bone-brain axis.

Entities:  

Mesh:

Substances:

Year:  2017        PMID: 29131244

Source DB:  PubMed          Journal:  Eur Rev Med Pharmacol Sci        ISSN: 1128-3602            Impact factor:   3.507


  21 in total

1.  Editorial: Bidirectional Communication Between Brain and Muscle.

Authors:  J E Morley
Journal:  J Nutr Health Aging       Date:  2018       Impact factor: 4.075

2.  Hybrid stimulation enhances torque as a function of muscle fusion in human paralyzed and non-paralyzed skeletal muscle.

Authors:  Keith R Cole; Shauna Dudley-Javoroski; Richard K Shields
Journal:  J Spinal Cord Med       Date:  2018-06-20       Impact factor: 1.985

Review 3.  A focused review of myokines as a potential contributor to muscle hypertrophy from resistance-based exercise.

Authors:  Stephen M Cornish; Eric M Bugera; Todd A Duhamel; Jason D Peeler; Judy E Anderson
Journal:  Eur J Appl Physiol       Date:  2020-03-06       Impact factor: 3.078

Review 4.  Hormesis in Health and Chronic Diseases.

Authors:  Xin Li; Tingting Yang; Zheng Sun
Journal:  Trends Endocrinol Metab       Date:  2019-09-11       Impact factor: 12.015

5.  In Addition to Poor Glycemic Control, a High Level of Irisin in the Plasma Portends Early Cognitive Deficits Clinically in Chinese Patients With Type 2 Diabetes Mellitus.

Authors:  Hongyan Lin; Yang Yuan; Sai Tian; Jing Han; Rong Huang; Dan Guo; Jiaqi Wang; Ke An; Shaohua Wang
Journal:  Front Endocrinol (Lausanne)       Date:  2019-09-13       Impact factor: 5.555

Review 6.  Irisin: A Hope in Understanding and Managing Obesity and Metabolic Syndrome.

Authors:  Lidia I Arhire; Laura Mihalache; Mihai Covasa
Journal:  Front Endocrinol (Lausanne)       Date:  2019-08-02       Impact factor: 5.555

Review 7.  Irisin as a Multifunctional Protein: Implications for Health and Certain Diseases.

Authors:  Paulina Korta; Ewa Pocheć; Agnieszka Mazur-Biały
Journal:  Medicina (Kaunas)       Date:  2019-08-15       Impact factor: 2.430

Review 8.  Irisin-Associated Neuroprotective and Rehabilitative Strategies for Stroke.

Authors:  Melissa Ann Huberman; Nathan D d'Adesky; Qismat Bahar Niazi; Miguel A Perez-Pinzon; Helen M Bramlett; Ami P Raval
Journal:  Neuromolecular Med       Date:  2021-07-03       Impact factor: 3.843

9.  Lower Serum Irisin Levels Are Associated with Increased Osteoporosis and Oxidative Stress in Postmenopausal.

Authors:  Ali Badr Roomi; Wassan Nori; Roaa Mokram Hamed
Journal:  Rep Biochem Mol Biol       Date:  2021-04

Review 10.  The Role of Irisin in Alzheimer's Disease.

Authors:  Oh Yoen Kim; Juhyun Song
Journal:  J Clin Med       Date:  2018-11-01       Impact factor: 4.241

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.